Ibalizumab: First HIV Drug to Get Orphan Drug Status for Salvage Patients

Shares of TaiMed Biologics Inc, which manufactures drugs to treat AIDS, soared 12.93 percent yesterday after its new TMB-355 drug for intravenous injection was granted orphan drug status in the US.

The company’s shares closed at NT$151.2 yesterday, outperforming the over-the-counter benchmark index, which ended up 0.56 percent.

The granting of orphan status could shorten the time it takes for

Source: Nelson Vergel's HIV Blog - October 21, 2014 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs